Biokin's EGFRxHER3 ADC Clears a Fourth China Trial in Lung Cancer

Chinese biotech Biokin said its EGFRxHER3 bispecific antibody-drug conjugate met its goal in a late-stage China trial in a genetically-defined form of lung cancer, the fourth China cancer trial the drug has cleared, while partner Bristol Myers Squibb runs a similar global study.

Biokin, the Chinese biotech that handed Bristol Myers Squibb the ex-China rights to one of the more closely watched cancer molecules in development, said its EGFRxHER3 bispecific antibody-drug conjugate succeeded in a late-stage trial in China in a genetically-defined form of lung cancer. It is the fourth China cancer trial the drug has cleared, according to Endpoints News, and it lands while Bristol Myers Squibb (BMY) runs a comparable study on a global footing.

Shares of Bristol Myers Squibb last closed at 66.05, up 2.20% on the day from a previous close of 64.63, with a session range of 65.00 to 66.38, as of 20:00 GMT on Aug. 18, 2026. That move ran against a soft tape: the S&P 500 tracker (SPY) closed at $767.45, down 0.68%, the Nasdaq 100 tracker (QQQ) at $717.51, down 1.69%, and the Dow tracker (DIA) at $532.91, down 0.24%.

What an EGFRxHER3 bispecific ADC actually does

An antibody-drug conjugate is a targeting antibody chemically tethered to a potent cell-killing payload. The antibody finds a protein on the surface of a tumour cell, the complex is drawn inside, and the payload is released where it can do damage — the point being to deliver chemotherapy-grade toxicity with less of the collateral harm that comes from dosing the whole body.

A bispecific ADC goes one step further. Instead of binding a single target, the antibody grips two — here EGFR and HER3, two receptors that sit on the surface of many solid tumours and that lung cancers in particular lean on for growth signalling. Requiring two handles rather than one is meant to improve how selectively the drug latches onto tumour tissue and how efficiently it is internalised. It is also meant to make resistance harder: a tumour that downregulates one target may still be caught by the other.

That mechanism is why the asset attracted a large pharmaceutical partner in the first place, and why each successive readout carries more weight than a single-indication result normally would. The question investors and oncologists are really asking is not whether the drug works in one setting, but whether the platform behaves consistently across tumour types and lines of therapy.

Why the fourth readout matters more than the first

Genetically-defined lung cancer means the trial enrolled patients selected by a specific mutation rather than by tumour location alone. Those populations are the natural first home for targeted agents: the biology is well characterised, the standard of care is defined, and response rates in biomarker-selected patients tend to be cleaner to read than in all-comer studies. They are also, by definition, smaller markets — which is why a franchise strategy built on repeated indications matters commercially.

Four cleared China trials is a pattern rather than an outcome. One positive study can reflect a favourable population, a permissive comparator, or luck. A sequence of them across cancer settings speaks to the molecule's underlying activity and, just as important, to a tolerability profile that holds up well enough for regulators and investigators to keep expanding the program. ADCs have historically failed less on efficacy than on safety — interstitial lung disease and haematologic toxicity have derailed more than one promising conjugate — so accumulating exposure without a program-stopping signal is itself information.

The caveat is that China trial results do not translate mechanically into global approvals. Regulators outside China, including the U.S. Food and Drug Administration, have grown more insistent that pivotal data include populations representative of the patients who would actually receive the drug. Standard of care in the comparator arm can also differ meaningfully between geographies, which affects how a control-arm result should be read. That is precisely the gap the Bristol Myers Squibb-led global study exists to close.

What it means for Bristol Myers Squibb

Bristol Myers Squibb is the partner carrying the molecule internationally, and that division of labour is now the standard shape of Western pharma's engagement with Chinese oncology innovation: the originating biotech runs deep, fast, cost-efficient China trials; the multinational funds and executes the global registrational package and takes the ex-China commercial rights.

For Bristol Myers Squibb, the strategic logic is straightforward. The company faces the loss of exclusivity cliff that overhangs most large-cap pharma, and in-licensed late-stage oncology assets are among the few ways to add revenue with a shorter development runway than starting from discovery. Each additional positive China readout is a de-risking event for the global study — not proof of success, but evidence that the target combination and the payload behave as designed in humans, repeatedly.

What it does not do is guarantee the global endpoint. The international trial has its own design, its own comparator, its own patient mix and its own statistical bar. A drug can succeed in one health system's treatment paradigm and post a narrower benefit in another where patients arrive at the trial having already had more prior lines of therapy.

What to watch from here

Three things determine whether this becomes a franchise rather than a regional success story. First, whether Biokin's China filings convert into approvals and how quickly the drug is reimbursed there — that establishes real-world safety and durability data at scale. Second, the timing and endpoint hierarchy of the Bristol Myers Squibb global study, since an overall-survival readout carries far more commercial weight than a progression-free-survival win alone. Third, the competitive field: HER3-directed and EGFR-directed conjugates are a crowded class, and being fourth to market in a biomarker-defined niche is a very different business from being first.

For now, the signal is directional. A fourth cleared trial in China does not make the global program a certainty, but it narrows the range of things that can go wrong with the molecule itself — leaving trial design, geography and competition as the live variables.

Key facts

• Bristol Myers Squibb (BMY) last close: 66.05, +2.20%, as of 20:00 GMT Aug. 18, 2026
• Asset: EGFRxHER3 bispecific antibody-drug conjugate from Biokin
• Milestone: Fourth China cancer trial cleared; latest in genetically-defined lung cancer
• Partner role: Bristol Myers Squibb leads a similar study on a global basis

Frequently asked questions

What did Biokin announce?

Biokin, a Chinese biotech, said its EGFRxHER3 bispecific antibody-drug conjugate passed a late-stage clinical trial in China in a genetically-defined form of lung cancer. The company described it as the fourth cancer trial the drug has cleared in China. Bristol Myers Squibb, Biokin's partner on the asset, is running a comparable study on a global basis.

What is a bispecific antibody-drug conjugate?

An antibody-drug conjugate links a targeting antibody to a potent cell-killing payload, delivering chemotherapy-strength toxicity preferentially to tumour cells. A bispecific version binds two targets instead of one — here EGFR and HER3 — which is intended to improve tumour selectivity, increase how efficiently the drug is taken into the cell, and make resistance harder for the tumour to develop.

How did Bristol Myers Squibb shares perform?

Bristol Myers Squibb last closed at 66.05, a gain of 2.20% from the prior close of 64.63, with a session range of 65.00 to 66.38, as of 20:00 GMT on Aug. 18, 2026. The market was closed at the time of writing. The broader tape was weaker that session, with the Nasdaq 100 tracker down 1.69%.

Does a positive China trial mean global approval is likely?

Not automatically. Regulators outside China, including the FDA, increasingly expect pivotal data to include populations representative of the patients who would receive the drug, and standard-of-care comparator arms can differ by geography. That is why Bristol Myers Squibb is running a separate global study with its own design, endpoints and patient mix.

Why does a fourth positive readout matter?

A single positive trial can reflect a favourable patient population or comparator. A repeated pattern across four cancer studies points to consistent underlying activity and a tolerability profile durable enough for investigators and regulators to keep expanding the program. For antibody-drug conjugates in particular, safety across accumulated exposure is a meaningful signal.

What should investors watch next?

Three markers: whether Biokin's China filings convert into approvals and reimbursement, the timing and endpoint structure of the Bristol Myers Squibb-led global study — an overall-survival result carries far more weight than progression-free survival alone — and the competitive field, since HER3- and EGFR-directed conjugates are a crowded development class.

Sources

• Bristol Myers' partner Biokin says bispecific ADC clears fourth cancer trial in China — Endpoints News

Photo: https://kaboompics.com/ · Pexels Licence — source